Investigational drug · Phase 2
Modzatinib
Also called: ATI-2138
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lichen Planus, Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
1
Any phase or sponsor naming "Modzatinib"
First trial start
2024
Aug 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Modzatinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lichen Planus
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Modzatinib" as an intervention, largest first.
- Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical TherapiesPivotal-lookingRecruiting
Aclaris Therapeutics, Inc.Industry
NCT07935590 · 102 participants (planned) · Start Nov 2026 · Primary completion Mar 2029
Drug: Modzatinib; Placebo · For: Lichen Planus
Sites: Savannah, Georgia
Newest research
PubMed records naming it or its code names, newest first.
- Characterization of the dual ITK/JAK3 small molecule covalent inhibitor ATI-2138.
Kaul A, Hope H, Xu C, et al. · J Pharmacol Exp Ther 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.